Key result
Compression therapy in patients with stable chronic heart failure reduced NYHA III prevalence from 53.5% at baseline to 32.6% at 1 month, without adverse events.
Why the study?
Compression therapy is widely used for edema, but concerns exist regarding its safety in patients with heart failure due to increased venous return potentially increasing pulmonary artery blood pressure.
Does compression therapy improve symptoms and reduce BNP safely in patients with stable chronic heart failure?
Cohort (n=101)
Does compression therapy improve symptoms and reduce BNP safely in patients with stable chronic heart failure?
Compression therapy appears safe and is associated with improved symptoms and reduced BNP levels in patients with stable chronic heart failure, particularly those with HFpEF.
Answers are grounded in this paper and cite their sources.
Supports cautious use for edema in stable chronic HF; leaves open confirmation via randomized trials.
Compression therapy is widely used as a therapeutic option for edema; however, concerns regarding its safety in patients with heart failure (HF) arose, particularly due to increased venous return, which increases pulmonary artery blood pressure. This study aimed to investigate the safety of compression therapy in patients with chronic HF. This study retrospectively enrolled patients with stable chronic HF who initiated treatment with compression therapy for lower extremity edema. The primary outcome was New York Heart Association (NYHA) class changes after 1 month of compression therapy, and adverse events were evaluated. We analyzed 101 patients who initiated compression therapy. The number of patients continuing compression therapy at one month was 86. Overall, 61.6 % were female and the median age was 81 years. The proportion of patients with heart failure and preserved ejection fraction (HFpEF) was 50.4 %. Brain natriuretic peptide levels were significantly lower than baseline levels at 1 month, (baseline vs 1 month: 486 (360–696) vs 311 (211–511), p < 0.001), with a lower NYHA III prevalence (baseline vs 1 month: 53.5 % vs 32.6 %, p < 0.001), without any adverse events related to compression therapy initiation. Additionally, multivariate logistic analysis indicated an association between HFpEF and significant BNP reduction after compression therapy (odds ratio: 4.70; 95 % confidence interval: 1.63–13.6). Compression therapy was associated with decreased BNP levels and improved symptoms, especially in HFpEF, without any adverse events in stable chronic HF. These findings indicate that compression therapy is safe for patients with stable chronic HF.
No takes yet. Share an insight, caveat, or question.
Nasu et al. (2024) conducted a cohort in Stable chronic heart failure with lower extremity edema (n=101). Compression therapy vs. Baseline was evaluated on New York Heart Association (NYHA) class changes after 1 month (p=<0.001). Compression therapy in patients with stable chronic heart failure reduced NYHA III prevalence from 53.5% at baseline to 32.6% at 1 month, without adverse events.
Synapse has enriched 10 related papers. Consider them for comparative context: